Results 41 to 50 of about 127,263 (196)
GRK Inhibition Potentiates Glucagon-Like Peptide-1 Action
Frontiers in Endocrinology, 2021 The glucagon-like peptide-1 receptor (GLP-1R) is a G-protein-coupled receptor (GPCR) whose activation results in suppression of food intake and improvement of glucose metabolism. Several receptor interacting proteins regulate the signaling of GLP-1R such
Seunghun P. Lee +7 more
doaj +1 more source
Allosteric optical control of a class B G-protein-coupled receptor [PDF]
, 2016 Allosteric regulation promises to open up new therapeutic avenues by increasing drug specificity at G‐protein‐coupled receptors (GPCRs). However, drug discovery efforts are at present hampered by an inability to precisely control the allosteric site ...
Broichhagen +20 more
core +1 more source
New perspectives on the use of glucagon-like peptide 1 in diseases of the central nervous system
Current Issues in Pharmacy and Medical Sciences, 2023 Glucagon-like peptide 1 is a neuromodulatory peptide that regulates the carbohydrate metabolism. It can cross the blood-brain barrier, and, indeed, while mostly produced in the distal small intestine and colon, it is also synthesized in the nucleus of ...
Lupina Malgorzata, Listos Joanna
doaj +1 more source
Glucagon-like peptide-1 analogues: An overview
Indian Journal of Endocrinology and Metabolism, 2013 Abnormalities of the incretin axis have been implicated in the pathogenesis of type 2 diabetes mellitus. Glucagon-like peptide-1 (GLP-1) and gastroinhibitory intestinal peptide constitutes >90% of all the incretin function.
Vishal Gupta
doaj +1 more source
Proglucagon-derived peptides do not significantly affect acute exocrine pancreas in rat
, 2015 Reports have suggested a link between treatment with glucagon-like peptide 1 (GLP-1) analogs and an increased risk of pancreatitis. Oxyntomodulin, a dual agonist of both GLP-1 and glucagon receptors, is currently being investigated as a potential ...
Akalestou, E +5 more
core +1 more source
Glucagon-like peptide 1 improved glycemic control in type 1 diabetes [PDF]
, 2003 Background Glucagon-like peptide-1 (GLP-1) and its agonists are under assessment in treatment of type 2 diabetes, by virtue of their antidiabetic actions, which include stimulation of insulin secretion, inhibition of glucagon release, and delay of ...
McDonald Thomas J +2 more
core +2 more sources
Glucagon-Like Peptide-1 and Diabetes [PDF]
Experimental Diabetes Research, 2011 This special issue was focused on the role and the effects of glucagon-like peptide-1 (GLP-1) in type 2 diabetes. This gastrointestinal hormone, which is mainly secreted after meals, enhances glucose-stimulated insulin release and inhibits food intake.
openaire +2 more sources
Glucagon‐like peptide‐1 receptor agonists and kidney outcomes
Journal of DiabetesGlucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have gained increasing attention for their potential benefits in people with type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD). Most supportive evidence of a kidney‐protective effect of
Richard J. MacIsaac +2 more
doaj +1 more source
Neural Regeneration Research, 2019 Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 receptor agonists is a breakthrough in the field of neural regeneration research increasing glucagon like peptide-1 bioavailability, hence its neuroprotective activities.
Shaker A Mousa, Bassam M Ayoub
doaj +1 more source
Microbiota-Produced N-Formyl Peptide fMLF Promotes Obesity-Induced Glucose Intolerance. [PDF]
, 2019 The composition of the gastrointestinal microbiota and associated metabolites changes dramatically with diet and the development of obesity. Although many correlations have been described, specific mechanistic links between these changes and glucose ...
Chan, Luisa S +16 more
core +1 more source